Bio tech company updates — 7/20/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea's biotech sector achieved a landmark milestone as Samsung Biologics announced a $1.8 billion acquisition of Switzerland's PolyPeptide Group—the largest M&A deal in Korean biotech history. Meanwhile, Korean biotech firms LigaChem Bio, ABL Bio, and Genome & Company are racing to develop next-generation antibody-drug conjugates (ADCs) to capture a share of big pharma's trillion-won cancer therapy investments. The Korea Biotechnology Industry Organization also strengthened regional ties by calling for closer bio supply chain cooperation with Taiwan.
Key Findings
Samsung Biologics announced a major strategic expansion by agreeing to acquire PolyPeptide Group of Switzerland for 2.7 trillion won ($1.8 billion USD), marking the largest M&A transaction in Korean biotech industry history. The deal values PolyPeptide at a 40 percent premium and positions Samsung Biologics to enter the lucrative GLP-1 obesity drug production sector.
Despite the acquisition's strategic importance, Samsung Biologics shares fell 1.86% in early trading following the announcement.
Korean biotechs LigaChem Bio, ABL Bio, and Genome & Company are actively developing next-generation ADCs with novel targets and dual payloads as major pharmaceutical companies pour billions into cancer therapy deals.
Details
Samsung Biologics' Strategic Pivot into Peptides
Samsung Biologics' acquisition of PolyPeptide represents a significant vertical expansion for the Korean contract manufacturing giant. The Switzerland-based PolyPeptide Group specializes in peptide synthesis and manufacturing, a critical component for next-generation therapeutics including GLP-1 receptor agonists currently dominating the obesity and diabetes treatment landscape.
The all-cash transaction values PolyPeptide at a 40 percent premium, reflecting Samsung Biologics' confidence in the strategic fit.
Korean ADC Pipeline Accelerates Amid Global Competition
Korean biotech companies are capitalizing on unprecedented global investment in antibody-drug conjugates. LigaChem Bio, ABL Bio, and Genome & Company are developing next-generation ADCs featuring novel molecular targets and dual-payload mechanisms designed to overcome resistance patterns seen in first-generation therapies.
This development comes as multinational pharmaceutical companies allocate trillions of won toward cancer therapeutic acquisitions and partnerships globally.
Regional Supply Chain Cooperation
The Korea Biotechnology Industry Organization (KoreaBIO) called for closer bio supply chain cooperation between South Korea and Taiwan at BIO Asia-Taiwan 2026, signaling efforts to strengthen regional biotech partnerships amid global supply chain restructuring.
Sources
Korean biotech eyes deals, partnerships at BIO 2026 - The Korea Herald
Korean Biotechs Race to Develop Next-Generation ADCs - Seoul Economic Daily
K-Bio Faces Capital Drought Despite Global Spotlight - Seoul Economic Daily
South Korea Stock Markets & Securities - Seoul Economic Daily
koreaherald.com
en.sedaily.com
koreaherald.com
easternherald.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
